Table 1.
Inhibitor name | Company | JAK1 | JAK2 | JAK3 | TYK2 | Citation |
---|---|---|---|---|---|---|
BMS-911543 | Bristol-Myers Squibb | 356 | 1 | 73 | 66 | Purandare et al., 2012 |
ruxolitinib (INCB018424) | Novartis | 3.3 | 2.8 | 428 | 19 | Quintas-Cardama et al., 2010 |
TG101209 | Sanofi-Aventis | ND | 6 | 169 | ND | Pardanani et al., 2007 |
tofacitinib (CP-960,550) | Pfizer | 112 | 20 | 1 | ND | Changelian et al., 2003 |
pacritinib (SB1518) | S*BIO | 1280 | 23 | 520 | 50 | William et al., 2011 |
momelotinib (CYT387) | Gilead | 11 | 18 | 155 | 17 | Tyner et al., 2010 |